The mRNA technologies that helped rapidly create effective Covid-19 vaccines could become technology platform businesses, which has tremendous implications for players the world of drug development. These platforms could attract other companies interested in exploiting their advantages to develop other drugs. But all the stakeholders — platform owners, external pharmaceutical and biotech companies, policymakers, and regulators — will have to make a variety of choices.